Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis
{{output}}
Fostamatinib was approved in Japan in December 2022 for primary immune thrombocytopenia (ITP). Given the limited clinical trial data, post-marketing surveillance (PMS) was conducted in Japan to collect safety and effectiveness data for fostamatinib. This inter... ...
